Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane)

NCT07369505 is registered in ClinicalTrials.gov with SAPU NANO (US) LLC as lead sponsor.

NCT NCT07369505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07369505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane)
Lead sponsor
SAPU NANO (US) LLC
Phase
Phase 1
Overall status
Recruiting
Start date
December 15, 2025
Completion date
December 31, 2026
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic, hepatocellular carcinoma (hcc), neuroendocrine tumors, renal cell carcinoma (rcc), tuberous sclerosis complex (tsc)